Abstracts tagged "Lupus nephritis"

Abstract Number: 2392 • ACR Convergence 2025
Does Obesity Influence Disease Activity and Biomarkers in Systemic Lupus Erythematosus Patients?: A Retrospective Study
Daniyal Nadeem¹, Anusheh Ali², Shravya Balmuri², Megan Mattison³, Upasana Agrawal⁴, Alexandra Zamora-Smith⁵, Karan Sachdeva⁶, Teresa leeth¹, Robert Quinet⁷, William Davis⁸, Jerald Zakem⁹, Chandana Keshavamurthy¹⁰, Xin Zhang¹¹, Sarwat Umer¹² and Samina Hayat¹³, ¹Louisiana State University Health Science, Shreveport, LA, ²Louisiana State University, Shreveport, LA, ³Louisiana State University- Shreveport, Shreveport, LA, ⁴Louisiana State University Health Sciences, Shreveport, Shreveport, LA, ⁵LSU Health Science Center in Shreveport, Shreveport, LA, ⁶Louisiana state university health shreveport, shreveport, ⁷Department of Rheumatology, Ochsner Health, New Orleans, LA, ⁸Ochsner Health System, New Orleans, LA, ⁹Ochsner Health Systems, Metairie, LA, ¹⁰banner university medical center, phoenix, AZ, ¹¹Ochsner Medical Center, New Orleans, LA, ¹²LSUHSC Shreveport, Shreveport, LA, ¹³Louisiana state university Shreveport, Shreveport, LA
Background/Purpose: Obesity, a prevalent condition, is known to exacerbate inflammation and could potentially influence the progression and severity of autoimmune diseases like Systemic lupus erythematosus…
Abstract Number: 1547 • ACR Convergence 2025
Anifrolumab In Systemic Lupus Erythematosus With Renal Involvement: National Multicenter Registry In Clinical Practice
Vanesa Calvo-Río¹, Carmen Secada-Gómez¹, Blanca Garcia-Magallon², Deseada Palma-Sanchez³, Andrea García-Valle⁴, Irati Urionaguena Onaindia⁵, Adrián Mayo-Juanatey⁶, Paúl Hernández Velasco⁷, GUILLERMO GONZALEZ ARRIBAS⁸, Ana Pareja-Martínez⁹, Montserrat Corteguera¹⁰, Guillen Sada Urmeneta¹¹, Paz Collado Ramos¹², Jose Luis Tandaipan¹³, Juan Roberto Miguelez Sanchez¹⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Rheumatology. Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, ⁴Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ⁵Rheumatology.Hospital Galdakao, Vizcaya, Pais Vasco, Spain, ⁶Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ⁷Nephrology, Hospital Universitario ¹² de Octubre, Madrid. Spain, Madrid, Madrid, Spain, ⁸Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ⁹Rheumatology. Hospital Universitario Infanta Leonor, Madrid, Madrid, Spain, ¹⁰Rheumatology. Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ¹¹Rheumatology. Hospital Reina Sofía, Tudela, Navarra, Spain, ¹²Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain, ¹³Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁴Department of Rheumatology, Hospital Universtiario de Móstoles, Madrid, Spain, Madrid, Madrid, Spain
Background/Purpose: Lupus Nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), occurring in up to 50% of patients. Currently, Anifrolumab (ANI) is approved…
Abstract Number: 1476 • ACR Convergence 2025
Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus: A Meta-Analysis of Prevalence and Clinical Correlates
Bana Shawareb¹, Muhannad Haddadin¹, Ansaam Daoud² and Omer Pamuk³, ¹Cleveland Clinic Akron General, Akron, OH, ²Case Western Reserve University/University Hospitals, Cleveland, OH, ³University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by widespread immune dysregulation and multi-organ involvement. Autoimmune hemolytic anemia (AIHA), marked by antibody-mediated…
Abstract Number: 0665 • ACR Convergence 2025
Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
Richard Furie¹, Teresa Baczkowska², Amit Saxena³, Imran Hassan⁴, Bongin Yoo⁵, Ben Lanza⁶, Himanshi Sehgal⁷, Frederic Boissard⁷, Jay Garg⁵, Thomas Schindler⁷, Elsa Martins⁷, William Pendergraft⁵ and Brad Rovin⁸, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ³Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁴Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸The Ohio State University, Columbus, OH
Background/Purpose: The REGENCY (NCT04221477) trial demonstrated superior efficacy of obinutuzumab and standard therapy (OBI+ST) over placebo and ST (PBO+ST) in patients (pts) with active lupus…
Abstract Number: 0612 • ACR Convergence 2025
Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Fadi Kharouf¹, JuanPablo Diaz Martinez², Pankti Mehta³, Dafna D. Gladman⁴, Laura Whitall Garcia⁵ and Zahi Touma⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarials, particularly hydroxychloroquine, are a cornerstone of systemic lupus erythematosus (SLE) management, with well-established benefits including reduced disease activity, prevention of flares, and mitigation…
Abstract Number: 2460 • ACR Convergence 2025
Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
Pablo Martínez Calabuig¹, Jorge Juan Fragío Gil², Roxana González Mazario³, Laura Salvador Maicas⁴, Mireia Sanmartin Martínez⁴, Iván Jesús Lorente Betanzos⁴, Amalia Rueda Cid⁴, Juan José Lerma Garrido⁴, Isabel Martínez Cordellat⁴, Isabel Balaguer Trull⁴, Berta Gómez Correas⁴ and Cristina Campos Fernández³, ¹Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ²Hospital General Universitario, Valencia, Spain, ³Hospital General de Valencia, Valencia, Spain, ⁴Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement and fluctuating activity. Biologic therapies such as Belimumab, Anifrolumab, and Rituximab offer…
Abstract Number: 2465 • ACR Convergence 2025
CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
chunmei Wu¹, Yakai Fu², Jia Liu³, Yan Ye⁴, Ran Wang⁵, Xintong Feng³, Lianjun Shen⁶, Peiying Li⁵, Shuang Ye⁵ and Qiong Fu⁷, ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ³Astrazeneca, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ⁶Astrazeneca, Shanghai, Shanghai, China (People's Republic), ⁷Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: GC012F (AZD0120) is a CD19/B cell maturation antigen (BCMA) dual-targeting chimeric antigen receptor T-cell (CAR-T) developed on the novel FasTCAR-T platform with next-day manufacturing,…
Abstract Number: 2381 • ACR Convergence 2025
Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis
Angela Lu¹, Daming Shao², Ying Jin¹, Luis Chiriboga³, Ming Wu⁴, James Pullman⁵, Anna Broder⁶ and Shudan Wang⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Chicago, Chicago, IL, ³NYU Langone Medical Center, New York City, ⁴Northwell Health, New Hyde Park, ⁵Montefiore Medical Center, Bronx, NY, ⁶Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: The complement system is known to play a central role in the pathogenesis of lupus nephritis (LN), one of the most severe manifestations of…
Abstract Number: 1546 • ACR Convergence 2025
Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response
Urvi Zala¹ and Rushi Patel², ¹Loyola MacNeal Hospital, Berwyn, IL, Oak Park, IL, ²Baptist Hospitals of Southeast Texas, Beumont, TX
Background/Purpose: Lupus nephritis (LN) is seen in approximately 40–60 % of patients with systemic lupus erythematosus (SLE) and contributes significantly to morbidity and mortality in…
Abstract Number: 1467 • ACR Convergence 2025
Risk Factors Associated with Chronic Kidney Disease and End-Stage Kidney Disease in Patients with Newly Diagnosed Lupus Nephritis
Aakash V. Patel¹, Lingxiao Zhang², Hyon K. Choi³ and April Jorge⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁴Massachusetts General Hospital, Boston, MA

Background/Purpose: Lupus nephritis (LN) affects over half of patients with systemic lupus erythematosus (SLE) and is associated with an increased risk for adverse kidney outcomes.…
Abstract Number: 0664 • ACR Convergence 2025
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Richard Furie¹, Ioannis Parodis², Rachel Jones³, Liz Lightstone⁴, Olivia Hwang⁵, Amelia Au-Yeung⁵, Imran Hassan⁶, Huiyan Mao⁶, William Pendergraft⁵, Jay Garg⁵, Harini Raghu⁵ and Brad Rovin⁷, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ³Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁴Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁵Genentech, Inc., South San Francisco, CA, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus, marked by kidney inflammation and damage. Obinutuzumab, a glycoengineered, type II CD20 antibody…
Abstract Number: 0610 • ACR Convergence 2025
The Role of Active Nephritis, Compared to Active Non-Renal SLE, in Pregnancy Outcomes
Emma Trachman¹, Amanda Eudy² and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: The ACR recommends against pregnancy in patients with SLE with high disease activity. These recommendations do not distinguish between the various manifestations of active…
Abstract Number: 2462 • ACR Convergence 2025
Precision Dosing is Needed to Establish Predictable Exposure to the Active Metabolite of Mycophenolate Mofetil (MMF) in Pediatric Lupus Nephritis (LN)
Pooja Patel¹, Eveline Wu², Laura Cannon³, Kristen Hayward⁴, Daryl Okamura⁵, Marietta De Guzman⁶, Ana Luiza Altaffer⁶, Stacy Ardoin⁷, Ellen Cody⁸, Takanobu Nadai⁹, Kei Irie⁹, Gabrielle Morgan¹⁰, Carolina Pastrana³, Angela Merritt⁹, Catherine Robben⁹, A. Carmela Sagcal-Gironella¹¹, Junfang Zhao⁹, Hermine Brunner¹² and Tomoyuki Mizuno⁹, ¹Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²UNC Chapel Hill, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Seattle Children's Hospital/University of Washington School of Medicine, Seattle, WA, ⁵Seattle Children's Hospital, Seattle, WA, ⁶Baylor College of Medicine, Houston, TX, ⁷Nationwide Children's Hospital, Columbus, OH, ⁸Medical College of Wisconsin, Milwaukee, WI, ⁹Cincinnati Childrens Hospital Medical Center, Cincinnati, OH, ¹⁰Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ¹¹Hackensack University Medical Center, Hackensack, NJ, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The safety and effectiveness of MMF for the treatment of LN have been tested in adult and pediatric patients. MMF, a prodrug, is rapidly…
Abstract Number: 2210 • ACR Convergence 2025
Changes in Treatment Pathways Over Time in Pregnancies with Active Lupus Nephritis
Dahima Cintron¹, Amanda Eudy², Michelle Petri³, Rebecca Fischer-Betz⁴, Abeer Mockbel⁵, Cecilia Nalli⁶, Laura Andreoli⁷, Angela Tincani⁸, Yair Molad⁹, Dafna D. Gladman¹⁰, Murray Urowitz¹¹, Stephen Balevic¹² and Megan Clowse¹³, ¹Duke Health, Durham, NC, ²Duke University, Raleigh, NC, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, ⁵Cairo University/Kasr- AlAiny Medical School, Cairo, Egypt, ⁶ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁷University of Brescia, Brescia, Brescia, Italy, ⁸ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ⁹Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²Duke University, Durham, NC, ¹³Duke University, Chapel Hill, NC
Background/Purpose: Women with SLE experience higher rates of adverse pregnancy outcomes. Among those with active SLE during pregnancy, lupus nephritis (LN) is associated with particularly…
Abstract Number: 1544 • ACR Convergence 2025
Voclosporin in Lupus Nephritis: Meta-Analysis of 6-Month and 1-Year Efficacy with 1-Year Safety Outcomes
Sri Laxmi Priya Sunkara¹, Ravi Medarametla², Megha Kotha³ and Wael Jarjour⁴, ¹White river medical center, batesville, AR, ²Mamata Medical College, Guntur, Andhra Pradesh, India, ³Ohio State University, Columbus, OH, ⁴The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN), is the most sever organ manifestation of systemic lupus erythematosus (SLE) and it contributes significantly to morbidity and mortality. . Standard…

« Previous Page
1
…
4
5
6
7
8
…
44
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].